# 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy

> **NCT02243176** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 689 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Saxagliptin
- **DRUG:** Acarbose

## Key facts

- **NCT ID:** NCT02243176
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 689 (ACTUAL)
- **Last updated:** 2017-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02243176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02243176, "24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02243176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*